Free Trial

Orgenesis (ORGS) Competitors

Orgenesis logo
$0.15 -0.85 (-85.00%)
As of 10/17/2025 10:24 AM Eastern

ORGS vs. MTEX, THAR, NXTC, GOVX, CMMB, EDSA, FBLG, BLRX, LPCN, and LEXX

Should you be buying Orgenesis stock or one of its competitors? The main competitors of Orgenesis include Mannatech (MTEX), Tharimmune (THAR), NextCure (NXTC), GeoVax Labs (GOVX), Chemomab Therapeutics (CMMB), Edesa Biotech (EDSA), FibroBiologics (FBLG), BioLineRx (BLRX), Lipocine (LPCN), and Lexaria Bioscience (LEXX). These companies are all part of the "pharmaceutical products" industry.

Orgenesis vs. Its Competitors

Orgenesis (NASDAQ:ORGS) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

Orgenesis has a beta of 2.63, indicating that its stock price is 163% more volatile than the S&P 500. Comparatively, Mannatech has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500.

In the previous week, Orgenesis' average media sentiment score of 0.00 equaled Mannatech'saverage media sentiment score.

Company Overall Sentiment
Orgenesis Neutral
Mannatech Neutral

Mannatech has a net margin of -3.46% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Mannatech's return on equity.

Company Net Margins Return on Equity Return on Assets
Orgenesis-3,827.81% N/A -130.18%
Mannatech -3.46%-48.60%-10.70%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Orgenesis
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Mannatech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 13.0% of Mannatech shares are owned by institutional investors. 5.7% of Orgenesis shares are owned by company insiders. Comparatively, 41.5% of Mannatech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Mannatech has higher revenue and earnings than Orgenesis.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Orgenesis$662K1.09-$55.36MN/AN/A
Mannatech$117.87M0.15$2.49M-$2.04-4.63

Summary

Mannatech beats Orgenesis on 6 of the 10 factors compared between the two stocks.

Get Orgenesis News Delivered to You Automatically

Sign up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ORGS vs. The Competition

MetricOrgenesisPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$720K$1.03B$6.14B$10.55B
Dividend YieldN/A4.84%5.72%4.84%
P/E RatioN/A1.2929.4727.34
Price / Sales1.09170.96567.66227.59
Price / CashN/A17.6325.8230.35
Price / Book-0.028.0312.436.69
Net Income-$55.36M-$7.47M$3.32B$276.46M
7 Day Performance-85.00%-0.09%1.84%-0.08%
1 Month PerformanceN/A29.45%8.84%3.93%
1 Year Performance-90.74%-12.99%63.12%33.89%

Orgenesis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ORGS
Orgenesis
1.5143 of 5 stars
$0.15
-85.0%
N/A-92.9%$720K$662K0.00150Gap Up
MTEX
Mannatech
0.2912 of 5 stars
$9.74
-3.2%
N/A+17.4%$18.51M$117.87M-4.77250Gap Up
High Trading Volume
THAR
Tharimmune
1.7774 of 5 stars
$3.12
+6.8%
$17.00
+444.9%
+44.3%$18.41MN/A-0.512Analyst Downgrade
Short Interest ↑
Gap Up
NXTC
NextCure
4.5556 of 5 stars
$6.72
+5.8%
$25.50
+279.5%
-34.2%$18.01MN/A-0.2690Short Interest ↓
Gap Down
GOVX
GeoVax Labs
2.3308 of 5 stars
$0.60
+8.7%
$8.50
+1,306.6%
-71.8%$17.95M$3.95M-0.3010
CMMB
Chemomab Therapeutics
2.4289 of 5 stars
$3.45
+2.7%
$26.50
+668.1%
-45.9%$17.84MN/A-1.4620High Trading Volume
EDSA
Edesa Biotech
2.0088 of 5 stars
$2.51
-1.2%
$5.00
+99.2%
-40.4%$17.67MN/A-1.9020
FBLG
FibroBiologics
2.5121 of 5 stars
$0.42
-4.2%
$12.67
+2,916.6%
-87.9%$17.59MN/A-1.1710High Trading Volume
BLRX
BioLineRx
1.7259 of 5 stars
$4.02
+4.4%
$26.00
+546.8%
-80.1%$17.49M$28.94M-0.4640
LPCN
Lipocine
1.8131 of 5 stars
$3.21
+3.2%
$8.00
+149.2%
-44.2%$17.40M$11.20M-3.6910Gap Down
LEXX
Lexaria Bioscience
2.3891 of 5 stars
$0.87
-3.2%
$4.00
+357.7%
-65.8%$17.10M$460K-1.307Short Interest ↑
Gap Up

Related Companies and Tools


This page (NASDAQ:ORGS) was last updated on 10/21/2025 by MarketBeat.com Staff
From Our Partners